ArticleClinical and experimental dental research2025
Tissue Biocompatibility and Antimicrobial Properties of Sympathomimetic Nasal Solutions for Potential Use in Dental Pulpal Management.
Article in Clinical and experimental dental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07675330 (Comparative Evaluation of Clinical and Radiographic Success of Oxymetazoline Versus Sodium Hypochlorite as Hemostatic Agents in MTA Pulpotomy of Primary Molars in a Group of Egyptian Children), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Evaluation of Clinical and Radiographic Success of Oxymetazoline Versus Sodium Hypochlorite as Hemostatic Agents in MTA Pulpotomy of Primary Molars in a Group of Egyptian Children: A Randomized Controlled Trial
Who cites it
2 citing papers in PubMed.
- An Oxymetazoline-Based Hemostatic Solution Used with MTA for Pulpal Therapy: A Retrospective Study.Children (Basel, Switzerland) · 2025Article
- Tissue Biocompatibility and Antimicrobial Properties of Sympathomimetic Nasal Solutions for Potential Use in Dental Pulpal Management.Clinical and experimental dental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesSympathomimetic nasal solutions (SNS), containing oxymetazoline or phenylephrine, may be used directly onto dental pulp tissue and initiate hemostasis via activation of alpha-receptors that innervate arteriole smooth muscles. The aim of this study was to assess these SNS's biocompatibility with human dental pulp stem cells (hDPSCs) and ability to kill a deep caries-associated pathogen, Rothia dentocariosa. MATERIALS AND
methodsA Kirby-Bauer disk diffusion susceptibility test assessed SNS zones of inhibition (ZOI) toward R. dentocariosa growth on agar plates. Over-the-counter (OTC) SNS containing 0.025% and 0.05% oxymetazoline (NS-OXY-kids, NS-OXY-original) and 1% phenylephrine (NS-PHE) were tested along with ingredients found in these nasal solutions: 0.025%, 0.05% oxymetazoline; 0.0125%, 0.025% benzalkonium chloride; and 0.2%, 1% phenylephrine (PHE). A second antimicrobial broth inhibition assay examined effects on R. dentocariosa planktonic growth. A 24-h recovery biocompatibility assay with resazurin (alamarBlue) was performed on hDPSC that were exposed to pure respective compound solutions, NS-OXY-kids, NS-PHE, and 1% PHE for 10 min.
resultsNS-OXY-kids, NS-OXY-original, NS-PHE, and 0.025% BKC were bactericidal toward R. dentocariosa with an average ZOI of (16.33 ± 2.22 [average ± SD] mm). NS-PHE had a small but statistically significant difference (17.83 ± 3.189 mm) between NS-OXY-kids (14.67 ± 1.033 mm); 0.0125% BKC had a smaller (p < 0.05) ZOI of 10.5 ± 0.837 mm. Solutions containing solely OXY (0.025%, 0.05%) and PHE (0.2%, 1%) demonstrated no bactericidal activity but had a slight bacteriostatic inhibition in the broth inhibition assay. The commercial OTC formulations of NS-PHE and NS-OXY-kids needed to be diluted 1:10 to have near 50% metabolic activity of hDPSCs normalized to untreated control cells.
conclusionsNS-PHE and NS-OXY (both original and kids) had antimicrobial activity toward R. dentocariosa and comparable biocompatibility with hDPSCs. SNS may have both hemostatic and antimicrobial properties if used as pulpal medicaments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.